Equity Profile

AMGN

Amgen Inc.

Health CareBiotechnology$209.2B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Amgen Inc. is a leading biotechnology company in the health care sector that focuses on developing innovative therapies for serious illnesses....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and reflects the company's financial health.

$5.62

Revenue

Revenue growth is crucial for assessing the company's ability to expand its market presence and support future innovations.

$9.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMGN Q2-2026 Earnings Preview

Context

Company Snapshot

Amgen Inc. is a leading biotechnology company in the health care sector that focuses on developing innovative therapies for serious illnesses. With a market cap of $209 billion, Amgen plays a significant role in advancing medical science and improving patient outcomes through its research and development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q1-2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. This positive surprise contributed to a 2.43% increase in stock price the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Amgen to report solid earnings driven by strong product demand, with a consensus EPS of $5.62 and revenue of $9.4 billion.

Bull Case

If Amgen beats expectations, it could signal robust demand for its therapies, potentially leading to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company misses estimates, it may raise concerns about its growth prospects and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$5.62

Earnings per share is a key indicator of profitability and reflects the company's financial health.

Revenue

$9.4B

Revenue growth is crucial for assessing the company's ability to expand its market presence and support future innovations.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amgen's EPS exceed the consensus estimate of $5.62?

A beat on EPS could indicate stronger-than-expected demand for its products and boost investor confidence.

What guidance will Amgen provide for future revenue growth?

Future revenue guidance will be critical for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating Amgen's ability to leverage its recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

Amgen has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

The options market is pricing a move that is higher than the historical average, suggesting that traders expect significant volatility.

Key Risk

If Amgen's revenue growth exceeds $9.6 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on Amgen's ability to maintain its growth trajectory amidst competitive pressures and market dynamics.

Bull Confirmed If

An EPS of $5.75 or higher would confirm strong demand and positive momentum.

Bear Confirmed If

An EPS below $5.50 could signal weakening performance and concerns about future growth.

Pre-Earnings Positioning

Options Market

Implied Move

±3.48%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a move of approximately 3.48%, indicating that traders expect some volatility around the earnings report.

Options are pricing ±3.5% while AMGN has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

24.6%

Calls (248K)P/C Ratio: 0.58Puts (419K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats expectations, history suggests a potential average one-day move of +2.43%, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further clarity on guidance.

Miss

A miss on earnings could lead to a decline, with history indicating an average one-day move of -2.45% when expectations are not met.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·1 sell

Members

House only

Est. Notional

$16,002.00–$65,000.00

disclosed dollar ranges

Most Active Members

R-FLMaria Elvira SalazarRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Details on cost management and pricing strategies in response to competition.
3Insights into pipeline developments and upcoming clinical trials.
4Management's outlook on market conditions and competitive landscape.
5Any commentary on regulatory changes that could impact operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Amgen Inc. is a leading biotechnology company in the health care sector that focuses on developing innovative therapies for serious illnesses....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and reflects the company's financial health.

$5.62

Revenue

Revenue growth is crucial for assessing the company's ability to expand its market presence and support future innovations.

$9.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q1-2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. This positive surprise contributed to a 2.43% increase in stock price the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Amgen to report solid earnings driven by strong product demand, with a consensus EPS of $5.62 and revenue of $9.4 billion.

Bull Case

If Amgen beats expectations, it could signal robust demand for its therapies, potentially leading to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company misses estimates, it may raise concerns about its growth prospects and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$5.62

Earnings per share is a key indicator of profitability and reflects the company's financial health.

Revenue

$9.4B

Revenue growth is crucial for assessing the company's ability to expand its market presence and support future innovations.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amgen's EPS exceed the consensus estimate of $5.62?

A beat on EPS could indicate stronger-than-expected demand for its products and boost investor confidence.

What guidance will Amgen provide for future revenue growth?

Future revenue guidance will be critical for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating Amgen's ability to leverage its recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

Amgen has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

The options market is pricing a move that is higher than the historical average, suggesting that traders expect significant volatility.

Key Risk

If Amgen's revenue growth exceeds $9.6 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on Amgen's ability to maintain its growth trajectory amidst competitive pressures and market dynamics.

Bull Confirmed If

An EPS of $5.75 or higher would confirm strong demand and positive momentum.

Bear Confirmed If

An EPS below $5.50 could signal weakening performance and concerns about future growth.

Pre-Earnings Positioning

Options Market

Implied Move

±3.48%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a move of approximately 3.48%, indicating that traders expect some volatility around the earnings report.

Options are pricing ±3.5% while AMGN has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

24.6%

Calls (248K)P/C Ratio: 0.58Puts (419K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats expectations, history suggests a potential average one-day move of +2.43%, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further clarity on guidance.

Miss

A miss on earnings could lead to a decline, with history indicating an average one-day move of -2.45% when expectations are not met.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·1 sell

Members

House only

Est. Notional

$16,002.00–$65,000.00

disclosed dollar ranges

Most Active Members

R-FLMaria Elvira SalazarRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Details on cost management and pricing strategies in response to competition.
3Insights into pipeline developments and upcoming clinical trials.
4Management's outlook on market conditions and competitive landscape.
5Any commentary on regulatory changes that could impact operations.